Compare AstraZeneca plc (AZN) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Nvidia Corp — how do they compare? AstraZeneca plc trades at $158.3 (market cap $250.84B), while Nvidia Corp trades at $218.4 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 21× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| AZN | NVDA | |
|---|---|---|
Market Cap | $250.84B | $5.27T |
Sector | Health | Technology |
52-Week High | $209.48 | $235.75 |
52-Week Low | $147.06 | $165.17 |
Enterprise Value | $278.12B | $5.20T |
Dividend Yield | 1.97% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
NVIDIA (NVDA) trades at $217.56, down 2.86% over 24 hours, amid a broader tech sell-off. The stock maintains strong fundamentals with Q1 2026 EPS beating estimates at $1.87 and a net income margin of 62.97%. Technical analysis shows a bullish trend with support at $215 and resistance at $222, while RSI indicates neutral momentum.
Outlook remains positive given robust AI-driven revenue growth and a $325.86 analyst price target, but risks include high valuation multiples and competitive pressures. The stock presents a long-term growth opportunity, though investors should monitor earnings sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
